Unsere Lösungen

Wir haben für alles eine Lösung – und die entsprechende Erfahrung. In unseren derzeit sieben Kompetenzbereichen stehen wir Ihnen mit unserem umfassenden Know-how mit Rat und Tat zur Seite.

Alle Lösungen

Willkommen in unserem virtuellen Showroom!

In unserem virtuellen Showroom präsentieren wir Ihnen unser umfangreiches Portfolio und Innovationen – rund um die Uhr!

Software

Software

Mit unserem Werum PAS-X MES – vor Ort oder in der Cloud installiert – und unseren Softwarelösungen für Datenanalyse, Track & Trace, vernetzte Fabriken und intelligente Verpackungen sind wir der weltweit führende Anbieter und Partner der Pharma- und Biotechindustrie.

Übersicht Software

Transportsysteme

Transportsysteme

Wir sind Spezialisten für komplette Transportsysteme im Bereich Pharma- und Medizinprodukte. Unsere Lösungen sind maßgebend im Bereich des kontaktlosen und sicheren Transports von z.B. Glasspritzen.

Übersicht Transportsysteme

Inspektionsmaschinen

Inspektion

Als weltweit führender Inspektionsexperte entwicklen wir Lösungen für die Pharma und Biotechindustrie. Unser Angebot reicht von Hochleistungsmaschinen und Halbautomaten über Laboreinheiten bis Inspektionsapplikationen für die Inprozesskontrolle.

Übersicht Inspektion

Maschinen-Finder

Verpackungsmaschinen

Verpackungsmaschinen

Wir sind führender Anbieter von Verpackungsmaschinen für flüssige und feste pharmazeutische- sowie für medizinische Produkte. Mit unseren Blister-, Sachet- und Stickpackmaschinen bieten wir Lösungen für Primärverpackungen. Unsere Side- und Topload-Kartonierer setzen weltweit Standards für die Sekundärverpackung.

Übersicht Verpackungsmaschinen

K.Pak Topload Case Packer

Introducing our latest solution from Körber; the K.Pak Topload Case Packer! Created specifically for the pharmaceutical industry, the K.Pak solution provides operator-friendly machines to complete any production line. Our solution focuses on innovative technology, high-quality design and expert handling and packaging of your product. It’s time to start connecting the dots with Körber!

Verpackungslösungen

Verpackungslösungen

Als langjährige Spezialisten entwickeln wir Verpackungslösungen für innovative und hochwertige Pharma-Sekundärverpackungen aus Karton. Wir bieten Ihnen Lösungen für Fälschungssicherheit, Standard- Faltschachteln und vieles mehr.

Übersicht Verpackungslösungen

Beratung

Beratung

Unsere Experten beraten Sie nach der Analyse Ihrer Anforderungen, zeigen Ihnen Optimierungspotenziale auf und unterstützen Sie bei der Implementierung von Projekten in allen Bereichen der Pharma-, Biotech- und Medizinproduktindustrie.

Übersicht Beratung

Blog

A primer to the digital pharma enterprise and the future role of MES

The global pharmaceutical industry is known for its ability to reinvent itself. The industry is renowned for its innovations across blockbuster drug discoveries, breakthroughs in biotechnology and ingenious consumer-driven business models. That said, the pharmaceutical industry has not been without its challenges. The industry, which gained remarkably due to globalization, is currently experiencing the downsides of the same. A changing demographic landscape and the demand for cheaper yet personalized medicine are examples of some of the formidable issues that require pharma companies to relook the way they design, engineer and manufacture drugs. In this context, we see that there are going to be 6 mega trends that will influence the pharma production philosophy going forward.

These include:

  1. Shift from batch to continuous manufacturing
  2. The role of CMO (contract manufacturing organization)
  3. Modularization
  4. Demand for generics and biosimilars
  5. The rise of precision medicine
  6. Pharma 4.0 – digital pharma enterprise

I intend to provide a heads-up on the topic of Pharma 4.0 – a trend that will act as the basis for the successful realization of many other mega trends enlisted above.

Pharma 4.0 and its implication

The Pharma 4.0 vision is an approach that tries to imbibe the ideals of the Industry 4.0 approach (from Smart Factories) into a shape and form that best fits the pharma production environment. It involves embracing new initiatives across product design, production process optimization (including primary and secondary), supply chain management and data-driven decision making. Some key attributes of this vision would include using digitalization as means to simplify supply chain complexity, achieving paperless manufacturing, creating low cost products at optimal OPEX, shortening new product innovation cycles, improving product quality and meeting regulatory needs more efficiently.

The aims of Pharma 4.0 are very high and there is, as expected, a lot of reticence within the industry. This will require suppliers (of Industry 4.0 solutions) to formulate solutions and the messaging thereof, to best fit the needs of pharma manufacturers. A core application that will sit in the middle of this approach will be the manufacturing execution system (MES). An effective MES strategy is a pre-requisite for realizing Pharma 4.0, acting as an engine that connects disparate production functions and housing invaluable process and business intelligence that can be accessed in real-time.

Given below are some key highlights that will determine the evolution of the Pharma industry going forward:

  1. Changing demographics and rise in chronic diseases will require pharma manufacturers to deliver cost effective drugs with short lead times.
  2. Medical diagnosis and treatment is gradually transitioning from “one-size-fits all” to precision medicine that tracks patient’s gene history.
  3. MES is expected to play a pivotal role in facilitating data transfer across the value chain, reducing product defects and improving product quality.
  4. With the emergence of Pharma 4.0, MES is poised to become the crux of an integrated enterprise ecosystem – connecting the shop floor with the top floor.

The journey towards realizing the Pharma 4.0 vision is riddled with challenges. Questions on return-on-investment (RoI) and the conservative nature of pharma manufacturers is certainly a major roadblock that will impede progress. However, the move towards the digital pharma enterprise is inevitable. Whilst the rest of the manufacturing industry moves forward, it is highly unlikely that the pharma industry will remain in the backseat. It can, on the contrary, become a bellwether in making the digital production possibilities a reality.

Kommentare

Keine Kommentare

Kommentar schreiben

* Diese Felder sind erforderlich

nach oben
nach oben